
Find Reports
Select Report Type
Reimbursement Review
Displaying 76 - 100 of 1264
Please scroll or swipe to the right to view the full content.
Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
---|---|---|---|---|---|---|---|---|
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0332-000 | |||
Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Complete | SR0806-000 | |||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Complete | SR0785-000 | |||
Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Complete | SR0793-000 | |||
Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Complete | PC0300-000 | |||
Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0330-000 | |||
Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | PC0324-000 | |||
Beqvez | fidanacogene elaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Complete | SG0802-000 | |||
Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0789-000 | |||
Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Complete | SR0788-000 | |||
Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0329-000 | |||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PC0320-000 | |||
Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0326-000 | |||
Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0323-000 | |||
Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0319-000 | |||
Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | SR0801-000 | |||
Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | SR0778-000 | |||
N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Complete | SX0777-000 | |||
Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | PC0328-000 | |||
Asparlas | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0321-000 | |||
N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | PX0318-000 | |||
Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | PC0313-000 | |||
Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | SR0775-000 | |||
Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | SR0782-000 | |||
Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ST0772-000 |
Health Technology Review
Displaying 76 - 100 of 590
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 76 - 100 of 111
Please scroll or swipe to the right to view the full content.
Projects in Progress
Displaying 26 - 39 of 39
View All Reports
Displaying 76 - 100 of 2100
Please scroll or swipe to the right to view the full content.
Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
---|---|---|---|---|---|---|---|
ravulizumab | Reimbursement Review | Active | SR0855-000 | ||||
brexucabtagene autoleucel | Reimbursement Review | Complete | PG0304-000 | ||||
Breast Cancer | Reimbursement Review | Provisional Funding Algorithm | In Progress | PH0083-000 | |||
Acute Myeloid Leukemia | Reimbursement Review | Provisional Funding Algorithm | In Progress | PH0082-000 | |||
Non-small Cell Lung Cancer | Reimbursement Review | Provisional Funding Algorithm | In Progress | PH0081-000 | |||
Non Small Cell Lung Cancer | Reimbursement Review | Provisional Funding Algorithm | Open for Stakeholder Input | PH0085-000 | |||
foslevodopa foscarbidopa | Reimbursement Review | Complete | SR0768-000 | ||||
Gastric cancer | Reimbursement Review | In Progress | PH0080-000 | ||||
Prostate cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0057-000 | |||
bulevirtide | Reimbursement Review | Pending | SR0881-000 | ||||
clascoterone | Reimbursement Review | Active | SR0863-000 | ||||
risankizumab | Reimbursement Review | Complete | SR0767-000 | ||||
alectinib | Reimbursement Review | Active | PC0350-000 | ||||
ferric carboxymaltose | Reimbursement Review | Active | SR0842-000 | ||||
Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC) | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0058-000 | |||
omaveloxolone | Reimbursement Review | Active | SR0864-000 | ||||
ferric carboxymaltose | Reimbursement Review | Active | SR0852-000 | ||||
ivosidenib | Reimbursement Review | Complete | PC0349-000 | ||||
odevixibat | Reimbursement Review | Pending | SR0884-000 | ||||
Virtual Mental Health Counselling | Health Technology Review | Rapid Review | Completed | RC1569-000 | |||
pasireotide | Reimbursement Review | Active | SR0859-000 | ||||
crovalimab | Reimbursement Review | Active | SR0858-000 | ||||
dostarlimab | Reimbursement Review | Active | PC0381-000 | ||||
pembrolizumab | Reimbursement Review | Active | PC0369-000 | ||||
pembrolizumab | Reimbursement Review | Active | PC0377-000 |